The European Commission (EC) has approved Pfizer’s Trumenba for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in adolescents and adults.
This age group is a critical demographic for vaccination against MenB due to inherent environmental and social risk factors such as close-quartered living and sharing behaviors.
Luis Jodar, Chief Medical and Scientific Affairs Officer, Medicines Development, Scientific and Clinical Affairs, Pfizer Vaccines, said: “Though uncommon, MenB disease is unpredictable, can progress rapidly and is associated with a significant risk of death and long-term disability, demonstrating the value of immunization as a preventive measure.”
Early symptoms can be misinterpreted as the flu, but meningococcal disease can lead to death within 24 hours.
Despite antibiotic treatment, 10 to 15% of people with meningococcal disease will die. Of those adolescents who survive, three in five experience significant physical and mental disabilities.
Adolescents remain a very important group for vaccination, as up to a quarter may be asymptomatic carriers of Neisseria meningitidis.